October 18, 2025Dermatology and TherapyOpen Access

Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series

View Full Paper

Ask AI

Bookmark

Combination therapy effectively improves HS activity and associated comorbid conditions.
All patients had failed multiple conventional therapies before combination treatment.
Combination of secukinumab and upadacitinib shows promise in managing refractory immune-mediated conditions.
Treatment was well tolerated without discontinuations or adverse events during follow-up.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case series reports significant HS improvement and resolution of immune-mediated comorbidities in patients, suggesting combination therapy's potential.

Cite This Study

Ramos et al. (2025) studied this question.

synapsesocial.com/papers/68f3b2fb3f213c1f8b4d34c4 https://doi.org/10.1007/s13555-025-01569-x

View Full Paper

Ask AI

Bookmark

Implication

Case series reports significant HS improvement and resolution of immune-mediated comorbidities in patients, suggesting combination therapy's potential.

Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series

Key Points

Discussion

Implication

Cite This Study

Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider